Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

Mease, Philip J

doi:10.1136/ard.61.4.298

Cited by 127 publications

(75 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,26,[32][33][34][35] Rare instances of more severe side effects, such as reactivation of pulmonary tuberculosis, aseptic meningitis, sepsis, and development of anti-dsDNA and systemic lupus, have occurred. Reactivation of TB has been hypothesized to occur as a consequence of the failure of granulomas to compartmentalize the bacilli and inhibition of macrophage apoptosis after the use of infliximab.…”

Section: Discussionmentioning

confidence: 97%

Successful Treatment of Von Zumbusch Pustular Psoriasis with Infliximab

Trent

Kerdel

2004

J Cutan Med Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Successful Treatment of Von Zumbusch Pustular Psoriasis with Infliximab

Trent

Kerdel

2004

J Cutan Med Surg

View full text Add to dashboard Cite

show abstract

“…Системные воспалительные про-цессы, происходящие при этом заболева-нии в различных структурах костно-сус-тавного аппарата, приводят к эрозирова-нию, необратимой резорбции суставных поверхностей и ограничениям функцио-нальных возможностей больных [1]. В па-тогенезе ПсА ведущую роль играют нару-шения функции иммунной системы, про-являющиеся гиперпродукцией провоспа-лительных цитокинов, в частности факто-ра некроза опухоли α (ФНОα), что в, ко-нечном счете, и определяет гетерогенность клинических проявлений ПсА [2]. Данный цитокин индуцирует продукцию других провоспалительных медиаторов, в частно-сти интерлейкина 1 (ИЛ1), ИЛ6, ИЛ8, ин-терферонов, хемокинов, а также фермен-тов, вызывающих деградацию хряща, включая матриксные металлопротеиназы [3].…”

Section: о б з о р ыunclassified

Efficacy of Certolizumab Pegol in the Treatment of Psoriatic Arthritis

Korotaeva¹,

Логинова²

2015

rsp

View full text Add to dashboard Cite

“…Darüber hinaus kam es bei 25% der Patienten (0% in der Placebogruppe) zu einer Verminderung des PA-SI-Scores um über 75%. Insgesamt wurde eine Verminderung des PASI um 46% erreicht (35). Diese Daten lassen vermuten, dass Etanercept eine vielversprechende Therapieoption zur Behandlung der Psoriasis und Psoriasis arthropathica werden könnte.…”

Section: Hemmung Der Wirkung Von Proinflammatorischen Zytokinen N Tnfunclassified

Einsatz von Biologicals bei Psoriasis in der Dermatologie

Friedrich

Philipp

Sabat

et al. 2003

Zeitschrift f�r Rheumatologie

View full text Add to dashboard Cite

With a prevalence of 2-3 percent, psoriasis is one of the most common diseases in dermatology. Most patients can be treated sufficiently with topical emollients, but approximately 20 percent of all patients suffering from psoriasis need photo- and/or systemic therapies. Side effects, contraindications, insufficient clinical responses, and lack of long-term efficacy underline the need for novel and improved antipsoriatic therapies. Several biologics interfering with key steps in the immunopathogenesis of psoriasis bear the potential to meet this need with regard to treating moderate to severe psoriasis. Progress made in the understanding of the pathophysiology of psoriasis as T-cell mediated dermatosis does provide options for new, more precise therapeutic approaches. These immunological therapeutic strategies are targeted at the inhibition of T-cell activation, the depletion of activated T-lymphocytes, the inhibition of adhesion of inflammatory cells, the inhibition of effects of proinflammatory cytokines and the application of antiinflammatory cytokines. This article gives a summary of new biologicals used in the treatment of psoriasis. Clinical results received from first applications are inconclusive. Further results of the studies from phase II and phase III can be expected in the next few years, which should make it possible to achieve better assessments of the potential of these types of treatments. Some of these approaches could lead to the approval of new drugs to treat psoriasis and to enhance or replace already existing therapeutic options.

show abstract

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

Cited by 127 publications

References 46 publications

Successful Treatment of Von Zumbusch Pustular Psoriasis with Infliximab

Successful Treatment of Von Zumbusch Pustular Psoriasis with Infliximab

Efficacy of Certolizumab Pegol in the Treatment of Psoriatic Arthritis

Einsatz von Biologicals bei Psoriasis in der Dermatologie

Contact Info

Product

Resources

About